Skip to main content
SpringerLink
Log in

Interactions Between Chemokines and Other Cytokines in Host Response to Tumor

  • Chapter
Chemokines and Cancer

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

This chapter focuses on interactions between chemokines and other cytokines that influence the nature of the host response to tumor. The basic structural and functional features of chemokines are presented in Chapters 1 and 2 in this volume, and a general discussion of these issues is therefore not provided here. The functional repertoire of the chemokine family is, however, known to encompass much beyond its ability to promote directed migration of leukocytes (1–4). Since the cooperative potential of individual chemokines for modulating host response to tumor is likely to be heavily influenced by the functional potential of each molecule, it is appropriate to provide a brief overview of such activities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Howard, O. M. Z., A. Ben-Baruch, and J. J. Oppenheim. 1996. Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol. 14: 46.

    Article  PubMed  CAS  Google Scholar 

  2. Negus, R. P. M. 1996. The chemokines: cytokines that direct leukocyte migration. J. R. Soc. Med. 89: 312.

    PubMed  CAS  Google Scholar 

  3. Rollins, B. J. 1997. Chemokines. Blood 90: 909.

    PubMed  CAS  Google Scholar 

  4. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392: 565.

    Article  PubMed  CAS  Google Scholar 

  5. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301.

    Article  PubMed  CAS  Google Scholar 

  6. Lollo, B. A., K. W. H. Chan, E. M. Hanson, V. T. Moy, and A. A. Brian. 1993. Direct evidence for two affinity states for lymphocyte function associated antigen-1 on activated T cells. J. Biol. Chem. 268: 21, 693.

    Google Scholar 

  7. Diamond, M. S., and T. A. Springer. 1993. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120: 545.

    Article  PubMed  CAS  Google Scholar 

  8. Snyderman, R., and R. J. Uhing. 1992. Chemoattractant stimulus-response coupling, in Inflammation: Basic Principles and Classical Correlates, 2nd ed. Gallin, J. I., I. M. Goldstein, and R. Snyderman, eds.), Raven, New York, p. 421.

    Google Scholar 

  9. Strieter, R. M., P. J. Polverini, D. A. Arenberg, A. Walz, G. Opdenakker, J. Van Damme, and S. L. Kunkel. 1995. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leuk. Biol. 57: 752.

    CAS  Google Scholar 

  10. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon inducible protein IP-10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182: 155.

    Article  PubMed  CAS  Google Scholar 

  11. Strieter, R. M., S. L. Kunkel, D. A. Arenberg, M. D. Burdick, and P. J. Polverini. 1995. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210: 51.

    Google Scholar 

  12. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182: 219.

    Article  PubMed  CAS  Google Scholar 

  13. Strieter, R. M., P. J. Polverini, D. A. Arenberg, and S. L. Kunkel. 1995. The role of CXC chemokines as regulators of angiogenesis. Shock 4: 155.

    Article  PubMed  CAS  Google Scholar 

  14. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877.

    PubMed  CAS  Google Scholar 

  15. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, M. Glass, M. D. Burdick, and R. M. Strieter. 1996 Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97: 2792.

    Article  PubMed  CAS  Google Scholar 

  16. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, T. I. Whyte, and R. M. Strieter. 1996. Interferon-gammainducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981.

    Article  PubMed  CAS  Google Scholar 

  17. Sgadari, C., A. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheik, G. Gupta, J. Teruya-Feldstein, and G. Tosato. 1996. Interferon inducible protein 10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93: 13, 791.

    Google Scholar 

  18. Broxmeyer, H. E., B. Sherry, S. Cooper, L. Lu, R. Maze, M. P. Beckmann, A. Cerami, and P. Ralph. 1993. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells: interacting effects involving suppression, synergistic suppression, and blocking of suppression. J. Immunol. 150: 3448.

    PubMed  CAS  Google Scholar 

  19. Youn, B.-S., I.-K. Jang, H. E. Broxmeyer, S. Cooper, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, T. A. Elick, M. J. Fraser, Jr., and B. S. Kwon. 1995. A novel chemokine, macrophage inflammatory protein-related protein-2, inhibits colony formation of bone marrow myeloid progenitors. J. Immunol. 155: 2661.

    PubMed  CAS  Google Scholar 

  20. Aronica, S. M., C. Mantel, R. Gonin, M. S. Marshall, A. Sarris, S. Cooper, N. Hague, X. F. Zhang, and H. E. Broxmeyer. 1995. Interferon-inducible protein 10 and macrophage inflammatory protein-la inhibit growth factor stimulation of Raf-1 kinase activity and protein synthesis in a human growth factor-dependent hematopoietic cell line. J. Biol. Chem. 270: 21, 998.

    Google Scholar 

  21. Schadendorf, D., A. Moller, B. Algermissen, M. Worm, M. Sticherling, and B. M. Czarnetzki. 1993. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151: 2667.

    PubMed  CAS  Google Scholar 

  22. Singh, R. K., K. Berry, K. Matsushima, K. Yasumoto, and I. J. Fidler. 1993. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages. J. Immunol. 151: 2786.

    PubMed  CAS  Google Scholar 

  23. Taub, D. D., T. J. Sayers, C. R. D. Carter, and J. R. Ortaldo. 1995. a and ß chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155: 3877.

    Google Scholar 

  24. Taub, D. D., J. R. Ortaldo, S. M. Turcovski-Corrales, M. L. Key, D. L. Longo, and W. J. Murphy. 1996. 13 Chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leuk. Biol. 59: 81.

    Google Scholar 

  25. Taub, D. D., S. M. Turcovski-Corrales, M. L. Key, D. L. Longo, and W. J. Murphy. 1996. Chemokines and T lymphocyte activation. I. 13 chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 156: 2095.

    PubMed  CAS  Google Scholar 

  26. Maghazachi, A. A., A. Al-Aoukaty, and T. J. Schall. 1996. CC chemokines induce the generation of killer cells from CD56+ cells. Eur. J. Immunol. 26: 315.

    Google Scholar 

  27. Chensue, S. W., K. S. Warmington, J. H. Ruth, P. S. Sanghi, P. Lincoln, and S. L. Kunkel. 1996. Role of monocyte chemoattractant protein-1 (MCP-1) in Thl (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation-relationship to local inflammation, Th cell expression, and IL-12 production. J. Immunol. 157: 4602.

    PubMed  CAS  Google Scholar 

  28. Karpus, W. J., and K. J. Kennedy. 1997. MIP-la and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Thl/Th2 lymphocyte differentiation. J. Leuk. Biol. 62: 681.

    CAS  Google Scholar 

  29. Karpus, W. J., N. W. Lukacs, K. J. Kennedy, W. S. Smith, S. D. Hurst, and T. A. Barrett. 1997. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol. 158: 4129.

    PubMed  CAS  Google Scholar 

  30. Gangur, V., F. E. Simons, and K. T. Hayglass. 1998. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J. 12: 705.

    PubMed  CAS  Google Scholar 

  31. Luster, A. D., and P. Leder. 1993. IP-10, a C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178: 1057.

    Article  PubMed  CAS  Google Scholar 

  32. Anderson, J. A., A. B. Lentsch, D. J. Hadjiminas, F. N. Miller, A. W. Martin, K. Nakagawa, and M. J. Edwards. 1996. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J. Clin. Invest. 97: 1952.

    Article  PubMed  CAS  Google Scholar 

  33. Cao, Y., C. Chen, J. A. Weatherbee, M. Tsang, and J. Folkman. 1995. gro-13, a CXC chemokine is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J. Exp. Med. 182: 2069.

    Google Scholar 

  34. Laning, J., H. Kawasaki, E. Tanaka, Y. Luo, and M. Dorf. 1994 Inhibition of in vivo tumor growth by the beta chemokine TCA3. J. Immunol. 153: 4625.

    PubMed  CAS  Google Scholar 

  35. Negus, R. P., and F. R. Balkwill. 1996. Cytokines in tumor growth, migration, and metastasis. World J. Urol. 14: 157.

    Article  PubMed  CAS  Google Scholar 

  36. Negus, R. P., G. W. Stamp, M. G. Relf, F. Burke, S. T. Malik, S. Bernasconi, P. Allavena, S. Sozzani, A. Mantovani, and F. R. Balkwill. 1995. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 95: 2391.

    Google Scholar 

  37. von Luettichau, I., P. J. Nelson, J. M. Pattison, M. van de Rijn, P. Huie, R. Warnke, C. J. Wiederman, R. A. Stahl, R. K. Sibley, and A. M. Krensky. 1996. RANTES expression in diseased and normal human tissues. Cytokine 8: 89.

    Article  PubMed  CAS  Google Scholar 

  38. Wiltrout, R. H., T. A. Gregorio, R. G. Fenton, D. L. Longo, P. Ghosh, W. J. Murphy, and K. L. Komschlies. 1995. Cellular and molecular studies in the treatment of murine renal cancer. Semin. Oncol. 22: 9.

    Google Scholar 

  39. Mazzucchelli, L., P. Loetscher, A. Kappeler, M. Uguccioni, M. Baggiolini, J. A. Laissue, and C. Mueller. 1996. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am. J. Pathol. 149: 501.

    PubMed  CAS  Google Scholar 

  40. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7: 1545.

    Article  PubMed  CAS  Google Scholar 

  41. Huang, S., R. K. Singh, K. Xie, M. Gutman, K. K. Berry, C. D. Bucana, I. J. Fidler, and M. Bar-Eli. 1994. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother. 39: 231.

    Google Scholar 

  42. Huang, S., K. Xie, R. K. Singh, M. Gutman, and M. Bar-Eli. 1995. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J. Interferon Cytokine Res. 15: 655.

    Article  PubMed  CAS  Google Scholar 

  43. Hoshino, Y., K. Hatake, T. Kasahara, Y. Takahashi, M. Ikeda, H. Tomizuka, T. Ohtsuki, M. Uwai, N. Mukaida, K. Matsushima, and Y. Miura. 1995. Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages into tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow. Exp. Hematol. 23: 1035.

    PubMed  CAS  Google Scholar 

  44. Hirose, K., M. Hakozaki, Y. Nyunoya, Y. Kobayashi, K. Matsushita, T. Takenouchi, A. Mikata, N. Mukaida, and K. Matsushima. 1995. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72: 708.

    Article  PubMed  CAS  Google Scholar 

  45. Manome, Y., P. Y. Wen, A. Hershowitz, T. Tanaka, B. J. Rollins, D. W. Kufe, and H. A. Fine. 1995. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol. Immunother. 41: 227.

    Article  PubMed  CAS  Google Scholar 

  46. Rollins, B., and M. E. Sunday. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell. Biol. 11: 3125.

    PubMed  CAS  Google Scholar 

  47. Rothenberg, M. E., A. D. Luster, and P. Leder. 1995. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. USA 92: 8960.

    Article  PubMed  CAS  Google Scholar 

  48. Dilloo, D., K. Bacon, W. Holden, W. Zhong, W. Burdach, A. Zlotnik, and M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances anti-tumor immunity. Nat. Med. 2: 1090.

    Article  PubMed  CAS  Google Scholar 

  49. Gattass, C. R., L. B. King, A. D. Luster, and J. D. Ashwell. 1994. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J. Exp. Med. 179: 1373.

    Article  PubMed  CAS  Google Scholar 

  50. Mule, J. J., and S. A. Rosenberg. 1991. Combination cytokine therapy: experimental and clinical trials, in Biological Therapy of Cancer. ( DeVita, V. T., S. Hellman, and S. A. Rosenberg, eds.), J. B. Lipincott, Philadelphia, p. 393.

    Google Scholar 

  51. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for IP-10 and Mig: structure, function and expression in activated T lymphocytes. J. Exp. Med. 184: 963.

    Google Scholar 

  52. Mackay, C. R. 1996. Chemokine receptors and T cell chemotaxis. J. Exp. Med. 184: 799.

    Article  PubMed  CAS  Google Scholar 

  53. Rutledge, B. R., H. Rayburn, R. Rosenberg, R. J. North, R. P. Gladue, C. Corless, and B. J. Rollins. 1995. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J. Immunol. 155: 4838.

    PubMed  CAS  Google Scholar 

  54. Butcher, E. C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67: 1033.

    Article  PubMed  CAS  Google Scholar 

  55. Norgauer, J., B. Metzner, and I. Schraufstatter. 1996. Expression and growth promoting function of the IL-8 receptor-f3 in human melanoma cells. J. Immunol. 156: 1132.

    PubMed  CAS  Google Scholar 

  56. Singh, R. K., and I. J. Fidler. 1993. Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes. Lymphokine Cytokine Res. 12: 285.

    PubMed  CAS  Google Scholar 

  57. Murphy, W. J., Z. G. Tian, O. Asai, S. Funakoshi, P. Rotter, M. Henry, R. M. Strieter, S. L. Kunkel, D. L. Longo, and D. D. Taub. 1996. Chemokines and T lymphocyte activation. 2. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J. Immunol. 156: 2104.

    PubMed  CAS  Google Scholar 

  58. Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 383.

    Google Scholar 

  59. D'Amore, P. A., and D. T. Shima. 1996. Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev. 15: 205.

    Article  PubMed  Google Scholar 

  60. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27.

    Article  PubMed  CAS  Google Scholar 

  61. Strieter, R. M., D. G. Remick, J. P. Lynch, R. N. Spengler, and S. L. Kunkel. 1989. Interleukin-2-induced tumor necrosis factor-alpha (TNF-a) gene expression in human alveolar macrophages and blood monocytes. Am. Rev. Respir. Dis. 139: 335.

    Article  PubMed  CAS  Google Scholar 

  62. Burdach, S., N. Zessack, D. Dilloo, M. Shatsky, D. Thompson, and L. Levitt. 1991. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor. J. Clin. Invest. 87: 2114.

    Article  PubMed  CAS  Google Scholar 

  63. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713.

    Article  PubMed  CAS  Google Scholar 

  64. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223.

    Article  PubMed  CAS  Google Scholar 

  65. Tahara, H., H. J. Zeh, III, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182.

    CAS  Google Scholar 

  66. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant interleukin-12 (IL-12) administration induces tumor regression in association with interferon-gamma production. J. Immunol. 153: 1697.

    PubMed  CAS  Google Scholar 

  67. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh, III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466.

    PubMed  CAS  Google Scholar 

  68. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156: 693.

    PubMed  CAS  Google Scholar 

  69. Dias, S., H. Thomas, and F. Balkwill. 1998. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int. J. Cancer 75: 151.

    Article  PubMed  CAS  Google Scholar 

  70. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17: 71.

    Article  CAS  Google Scholar 

  71. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, M. Dvorozniak, A. Aglione, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni. 1996. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38 (Suppl.): S16.

    Article  PubMed  CAS  Google Scholar 

  72. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC Chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161: 927.

    Google Scholar 

  73. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by Interleukin 12. JNCI 87: 581.

    Article  PubMed  CAS  Google Scholar 

  74. Porgador, A., B. Gansbacher, R. Bannerji, E. Tzehoval, E. Gilboa, M. Feldman, and L. Eisenbach. 1993. Anti-metastatic vaccination of tumor-bearing mice with IL-2-geneinserted tumor cells. Int. J. Cancer 53: 471.

    Article  PubMed  CAS  Google Scholar 

  75. Porgador, A., R. Bannerji, Y. Watanabe, M. Feldman, E. Gilboa, and L. Eisenbach. 1993. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-y gene-inserted tumor cells. J. Immunol. 150: 1458.

    PubMed  CAS  Google Scholar 

  76. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539.

    Article  PubMed  CAS  Google Scholar 

  77. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155: 1393.

    Google Scholar 

  78. Simmons, J. W., E. M. Jaffee, C. E. Weber, H. L. Levitsky, W. G. Nelson, M. A. Carducci, A. J. Lazenby, L. K. Cohen, C. C. Finn, S. M. Clift, K. M. Hauda, L. A. Beck, K. M. Leiferman, A. H. Owens, Jr., S. Piantadosi, G. Dranoff, R. C. Mulligan, D. M. Pardon, and F. F. Marshall. 1997. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex-vivo granulocyte-macrophage-colony stimulating factor gene transfer. Cancer Res. 57: 1537.

    Google Scholar 

  79. Gilboa, E. 1996. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 23: 101.

    PubMed  CAS  Google Scholar 

  80. Vieweg, J., F. M. Rosenthal, R. Bannerji, W. D. Heston, W. R. Fair, B. Gansbacher, and E. Gilboa. 1994. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54: 1760.

    PubMed  CAS  Google Scholar 

  81. Saito, S., R. Bannerji, B. Gansbacher, F. M. Rosenthal, P. Romanenko, W. D. Heston, W. R. Fair, and E. Gilboa. 1994. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54: 3516.

    PubMed  CAS  Google Scholar 

  82. Jaffee, E. M., and D. M. Pardon. 1995. Gene therapy: its potential applications in the treatment of renal-cell carcinoma. Semin. Oncol. 22: 81.

    PubMed  CAS  Google Scholar 

  83. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147: 729.

    PubMed  CAS  Google Scholar 

  84. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56: 4338.

    PubMed  CAS  Google Scholar 

  85. Inoue, M., G. E. Plautz, and S. Shu. 1996. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res. 56: 4702.

    PubMed  CAS  Google Scholar 

  86. Chang, A. E., and S. Shu. 1996. Current status of adoptive immunotherapy of cancer. Crit. Rev. Oncol. Hematol. 22: 213.

    Article  PubMed  CAS  Google Scholar 

  87. Mitsuma, S., H. Yoshizawa, K. Ito, H. Moriyama, M. Wakabayashi, T. Chou, M. Arakwa, and S. Shu. 1994. Adoptive immunotherapy mediated by anti-TCR/IL-2 activated tumor-draining lymph node cells. Immunology 83: 45.

    PubMed  CAS  Google Scholar 

  88. Chang, A. E., A. Aruga, M. J. Cameron, V. K. Sondak, D. P. Normolle, B. A. Fox, and S. Y. Shu. 1997. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15: 796.

    PubMed  CAS  Google Scholar 

  89. Kagamu, H., and S. Shu. 1998. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160: 3444.

    PubMed  CAS  Google Scholar 

  90. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Thl)-specific immune response and inhibits the development of IL-4producing Th cells. J. Exp. Med. 177: 1199.

    Article  PubMed  CAS  Google Scholar 

  91. Seder, R. A., A. Gazzinelli, A. Scher, and W. E. Paul. 1993. IL-12 acts directly on CD4+ T cells to enhance priming for IFNy production and diminishes IL-4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90: 10, 188.

    Google Scholar 

Download references

Authors
  1. Thomas A. Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles S. Tannenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Barrett J. Rollins MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hamilton, T.A., Tannenbaum, C.S., Finke, J., Bukowski, R. (1999). Interactions Between Chemokines and Other Cytokines in Host Response to Tumor. In: Rollins, B.J. (eds) Chemokines and Cancer. Contemporary Cancer Research. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-701-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-701-7_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4760-7

  • Online ISBN: 978-1-59259-701-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation